middle.news
Racura Oncology Advances Lung Cancer Trials with $34.3 Million Cash Backing
9:12am on Tuesday 28th of July, 2026 AEST
•
Biotechnology
Read Story
Racura Oncology Advances Lung Cancer Trials with $34.3 Million Cash Backing
9:12am on Tuesday 28th of July, 2026 AEST
Key Points
First patient treated in Phase 1 HARNESS-1 lung cancer trial
RC220 dose escalated to 80mg/m² in CPACS trial with no safety concerns
Preclinical data confirms RC220 silences c-MYC oncogene
Raised $18 million in the quarter, cash runway into 2028
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE